Suppr超能文献

胃癌的劳伦分类与个体化化疗

Lauren classification and individualized chemotherapy in gastric cancer.

作者信息

Ma Junli, Shen Hong, Kapesa Linda, Zeng Shan

机构信息

Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China; Key Laboratory for Molecular Radiation Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.

Key Laboratory for Molecular Radiation Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China; Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.

出版信息

Oncol Lett. 2016 May;11(5):2959-2964. doi: 10.3892/ol.2016.4337. Epub 2016 Mar 16.

Abstract

Gastric cancer is one of the most common malignancies worldwide. During the last 50 years, the histological classification of gastric carcinoma has been largely based on Lauren's criteria, in which gastric cancer is classified into two major histological subtypes, namely intestinal type and diffuse type adenocarcinoma. This classification was introduced in 1965, and remains currently widely accepted and employed, since it constitutes a simple and robust classification approach. The two histological subtypes of gastric cancer proposed by the Lauren classification exhibit a number of distinct clinical and molecular characteristics, including histogenesis, cell differentiation, epidemiology, etiology, carcinogenesis, biological behaviors and prognosis. Gastric cancer exhibits varied sensitivity to chemotherapy drugs and significant heterogeneity; therefore, the disease may be a target for individualized therapy. The Lauren classification may provide the basis for individualized treatment for advanced gastric cancer, which is increasingly gaining attention in the scientific field. However, few studies have investigated individualized treatment that is guided by pathological classification. The aim of the current review is to analyze the two major histological subtypes of gastric cancer, as proposed by the Lauren classification, and to discuss the implications of this for personalized chemotherapy.

摘要

胃癌是全球最常见的恶性肿瘤之一。在过去的50年里,胃癌的组织学分类主要基于劳伦标准,其中胃癌被分为两种主要的组织学亚型,即肠型和弥漫型腺癌。该分类于1965年提出,目前仍被广泛接受和应用,因为它是一种简单而可靠的分类方法。劳伦分类提出的胃癌两种组织学亚型表现出许多不同的临床和分子特征,包括组织发生、细胞分化、流行病学、病因学、致癌作用、生物学行为和预后。胃癌对化疗药物表现出不同的敏感性且具有显著的异质性;因此,该疾病可能是个体化治疗的靶点。劳伦分类可为晚期胃癌的个体化治疗提供依据,这在科学领域越来越受到关注。然而,很少有研究调查以病理分类为指导的个体化治疗。本综述的目的是分析劳伦分类提出的胃癌两种主要组织学亚型,并讨论其对个体化化疗的意义。

相似文献

1
Lauren classification and individualized chemotherapy in gastric cancer.
Oncol Lett. 2016 May;11(5):2959-2964. doi: 10.3892/ol.2016.4337. Epub 2016 Mar 16.
2
Clinicopathological Variation of Lauren Classification in Gastric Cancer.
Pathol Oncol Res. 2016 Jan;22(1):197-202. doi: 10.1007/s12253-015-9996-6. Epub 2015 Oct 27.
4
Comparison of endoscopic gastritis based on Kyoto classification between diffuse and intestinal gastric cancer.
World J Gastrointest Endosc. 2021 May 16;13(5):125-136. doi: 10.4253/wjge.v13.i5.125.
6
Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system.
J Surg Oncol. 2017 Aug;116(2):184-194. doi: 10.1002/jso.24648. Epub 2017 May 5.

引用本文的文献

1
Tumour budding in gastric and colorectal cancers: A review.
Medicine (Baltimore). 2025 Aug 1;104(31):e42215. doi: 10.1097/MD.0000000000042215.
2
Precancerous pathways to gastric cancer: a review of experimental animal models recapitulating the correa cascade.
Front Cell Dev Biol. 2025 Jul 2;13:1620756. doi: 10.3389/fcell.2025.1620756. eCollection 2025.
4
Classical biomarkers and non-coding RNAs associated with diagnosis and treatment in gastric cancer.
Oncol Res. 2025 Apr 18;33(5):1069-1089. doi: 10.32604/or.2025.063005. eCollection 2025.
6
The application of artificial intelligence in upper gastrointestinal cancers.
J Natl Cancer Cent. 2024 Dec 27;5(2):113-131. doi: 10.1016/j.jncc.2024.12.006. eCollection 2025 Apr.
8
Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates.
Cell Death Discov. 2025 Apr 5;11(1):144. doi: 10.1038/s41420-025-02429-5.

本文引用的文献

1
Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.
Mol Cancer Ther. 2016 Mar;15(3):402-11. doi: 10.1158/1535-7163.MCT-15-0644. Epub 2016 Feb 1.
2
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
Oncotarget. 2016 Sep 27;7(39):64431-64446. doi: 10.18632/oncotarget.7043.
4
Targeted therapy for gastric cancer: Current status and future directions (Review).
Oncol Rep. 2016 Mar;35(3):1245-54. doi: 10.3892/or.2015.4528. Epub 2015 Dec 29.
5
Trop2 is overexpressed in gastric cancer and predicts poor prognosis.
Oncotarget. 2016 Feb 2;7(5):6136-45. doi: 10.18632/oncotarget.6733.
6
Clinicopathological Variation of Lauren Classification in Gastric Cancer.
Pathol Oncol Res. 2016 Jan;22(1):197-202. doi: 10.1007/s12253-015-9996-6. Epub 2015 Oct 27.
7
Epigenetic alterations in gastric cancer (Review).
Mol Med Rep. 2015 Sep;12(3):3223-3230. doi: 10.3892/mmr.2015.3816. Epub 2015 May 22.
8
Familial gastric cancer: genetic susceptibility, pathology, and implications for management.
Lancet Oncol. 2015 Feb;16(2):e60-70. doi: 10.1016/S1470-2045(14)71016-2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验